Dabrafenib-Trametinib Combo Shows Activity as Second-Line Adjuvant Therapy in Advanced Melanoma
Source: Cancer Therapy Advisor, December 2024
Second-line adjuvant treatment with dabrafenib and trametinib appeared effective in a small study of patients with BRAF V600-mutated, resected, stage III/IV melanoma, researchers found. In fact, more than 80% of patients were free from relapse and metastasis at 1 year. These results were published in The Oncologist.
This retrospective study included 38 patients with BRAF V600-mutated, stage III/IV melanoma. The patients underwent resection to no evidence of disease, received first-line adjuvant treatment with immune checkpoint inhibitors, and relapsed during or after the first-line treatment. The patients underwent complete resection again and received second-line adjuvant treatment with dabrafenib and trametinib.
The patients’ median age at the start of dabrafenib-trametinib treatment was 52 years, 63.2% of patients were men, and 86.8% had stage III disease. As first-line adjuvant treatment, patients had received nivolumab alone (73.7%), pembrolizumab alone (15.8%), nivolumab plus ipilimumab (7.9%), or ipilimumab alone (2.6%).